C34 C61 C50 C67 C56 C00-C14 C18 C22 C25
Conditions
Interventions
Group 1: Study participants with cancer of the lung, prostate, breast, head or neck, are informed in detail about the course, risks, and benefits of the study. If consent is given, 10 mL of blood (onl
Sponsors
Ludwig-Maximilians Universität München, Fakultät für Physik,
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • Adults > 18 years who are able to consent to this study. • For tumor patients: confirmed tumor located in the lung, prostate, breast, head or neck. • For control group: patients with benign diagnoses. • The study participant has consented to participation in this study
Exclusion criteria
Exclusion criteria: Patients who are not able to consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • Area underneath the receiver operating characteristic function (AUC) of spectral features (GMFs) for discriminating blood samples of patients with confirmed lung, prostate, breast, and head and neck carcinoma and control patients with other pathologies. Spectral features are derived using laser-based infrared spectrosopy. | — |
Secondary
| Measure | Time frame |
|---|---|
| • Proteomic profiles from mass spectrometry of blood samples of patients with confirmed lung, prostate and breast carcinoma and patients with other diseases. • Routine clinical data, including medical imaging data and currently used biomarkers, of patients with confirmed lung, prostate and breast carcinoma and patients with other diseases. | — |
Countries
Germany
Contacts
Public ContactJacqueline Hermann
Klinik und Poliklinik für Radiologie; Klinikum der Universität München;
Outcome results
None listed